Tuesday 25 August 2020

BioLargo to Present at The LD 500 Virtual Conference

LOS ANGELES, CA / ACCESSWIRE / August 25, 2020 / BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies and a full-service environmental engineering company, today announced that it will be presenting at the LD 500 Investor Conference on Tuesday, September 1, 2020 at 8:00 AM PST / 11:00 AM EST. BioLargo President & CEO Dennis P. Calvert will be presenting to a live virtual audience of prospective investors.

A major focus of Mr. Calvert’s presentation will be Clyraguard Personal Protection Spray. BioLargo’s subsidiary Clyra Medical Technologies recently launched Clyraguard, a safe, effective, FDA-registered disinfectant for use on personal protection equipment (PPE) like facemasks. The company is currently ramping up distribution and sales of the new product through agreements with several contract manufacturers and a major national healthcare products distributor.

Mr. Calvert will also discuss the company’s per- and polyfluoroalkyl substance (PFAS) treatment technology, the BioLargo AEC, which is expected to begin its first pilots and commercial trials in late 2020 and early 2021. PFAS are a persistent and widespread class of contaminants of emerging concern globally due to their ability to cause serious health problems in humans and because of the difficulty with which they are removed from water. The BioLargo AEC has been proven capable of 99%+ PFAS removal from water in continuous flow and expects to be a low cost high efficiency solution for industry.

Register here: https://ld500.ldmicro.com/

"We have been waiting for this moment all year long. Due to COVID, it has been nearly impossible for physical conferences to even take place. I want to show the world that you can still learn, have a great time, and see some of the most unique companies in the capital markets today. All without having to step foot outside. For the first time, LD Micro is accessible to everyone, and we are honored to welcome you to one of the most trusted platforms in the space.” stated Chris Lahiji, Founder of LD Micro.

The LD 500 will take place on September 1st through the 4th.

View BioLargo’s profile here: http://www.ldmicro.com/profile/BLGO


Profiles powered by LD Micro — News Compliments of Accesswire

 

About BioLargo, Inc.

BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to “make life better”.  We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, ONM Environmental, Inc. (www.onmenvironmental.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and technology licensor to our subsidiary Clyra Medical which features its breakthrough product Clyraguard ( www.clyramedical.com/clyraguard), an FDA Registered, hospital grade disinfectant for personal protective equipment including facemasks, proven 99.999% effective against viruses and bacteria, and safe for skin, as well as its other products offering gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

About LD Micro

Back in 2006, LD Micro began with the sole purpose of being an independent resource to the microcap world.

What started as a newsletter highlighting unique companies, has transformed into the pre-eminent event platform in the space.

The upcoming "500" in September is the Company's most ambitious project yet, and the first event that is accessible to everyone.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

Contact:

Name: Dennis P. Calvert

Phone: 888-400-2863

Email: dennis.calvert@biolargo.com

Source: BioLargo, Inc. via LD Micro

 

BioLargo Announces Municipal Wastewater Treatment Pilot

Westminster, CA – August 25, 2020 – BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies and a full-service environmental engineering company, announced today that its first municipal wastewater treatment demonstration pilot of its AOS and AEC water treatment technologies will take place at a wastewater treatment plant near Montréal, Québec. Experts in water treatment and technology development from the Centre des Technologies de L’Eau (CTE) will supervise and validate the performance of the pilot on-site.

The purpose of the pilot is to assess BioLargo’s proprietary water treatment technologies – the Advanced Oxidation System (AOS) and Aqueous Electrostatic Concentrator (AEC) – as effective, cost-efficient, and complementary solutions for disinfecting and eliminating a broad range of recalcitrant contaminants from municipal wastewater in an operating wastewater treatment plant. The AOS and AEC have previously been shown to effectively remove hard-to-treat contaminants such as pharmaceutical pollutants, as well as other micropollutants like per- and poly-fluoroalkyl substances (PFAS), respectively.

This new pilot comes shortly after the successful conclusion of the company’s first demonstration pilot for the AOS technology at a poultry farm and processing facility near Edmonton, Alberta, where the technology was proven capable of providing effective and affordable treatment of poultry wastewater to the U.S. EPA’s safe water discharge standards. In keeping with BioLargo’s business plan, the company next sought to demonstrate the technology in a municipal wastewater treatment application.

The joint AOS/AEC demonstration pilot is funded in part by the Canadian Natural Science and Engineering Research Council (NSERC), through an Applied Research and Development (ARD) program grant, which will provide $225,000 CAD for the project. BioLargo’s engineers and scientists are building the AOS and AEC units for the pilot, and hope to have them installed and running by the end of October. Because of the pilot’s scope, the company expects to report initial results in the first quarter of 2021.

BioLargo Water President Dr. Richard Smith commented. “This is an extremely exciting pilot for us. The BioLargo AOS and AEC technologies have the potential to provide myriad benefits to municipal wastewater treatment operators, including reducing operating costs, greater breadth of treatment capabilities, and greater energy efficiency.”

The CTE is a recognized college research center for technology transfer attached to the college of Saint-Laurent in Montreal, Quebec. The mission of CTE is to carry out applied research and development activities, technical assistance, and information dissemination in the field of water technologies. The pilot project is led by the CTE researcher Dr. Rimeh Daghrir, expert in the development of advanced electrochemical technology and the remediation of micro-pollutants from water.

Dr. Daghrir commented, “We are very excited to help move the AOS program along to commercialization. These pilot assays will generate real-time data to show the AOS performance in a real wastewater stream. This AOS innovative technology developed by BioLargo Water is positioned in the water treatment market as an effective and cost-efficient tool for the disinfection and the decontamination of persistent organic pollutants such as the residual of pharmaceutical products. Certainly, this advanced pilot combining AOS technology to AEC system offers an innovative and sustainable solution to problems of water conservation and high cost of industrial water use because it is an extremely powerful, safe, and cost-effective water treatment platform. Thanks to this successful collaboration with BioLargo, funded by NSERC, we have succeeded in training highly qualified experts and graduating students from the Department of Water Technology of the College Saint-Laurent in the environmental electro-technology field.”

About BioLargo, Inc.

BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to “make life better”.  We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, ONM Environmental, Inc. (www.onmenvironmental.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and technology licensor to our subsidiary Clyra Medical which features its breakthrough product Clyraguard ( www.clyramedical.com/clyraguard), an FDA Registered, hospital grade disinfectant for personal protective equipment including facemasks, proven 99.999% effective and safe for skin, as well as its other products offering gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

During the course of the stockholder presentation, BioLargo may make “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995, regarding future events or the future financial performance of the company that are subject to change. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

 

Wednesday 19 August 2020

BioLargo Covers its Diverse Portfolio with The Stock Day Podcast

Phoenix, Arizona--(Newsfile Corp. - August 19, 2020) - The Stock Day Podcast welcomed BioLargo, Inc. (OTCQB: BLGO) ("the Company"), an innovator of technology-based products and environmental engineering solutions provider. BioLargo President & CEO Dennis Calvert joined Stock Day host Everett Jolly.

Jolly began the interview by asking about the Company's 10-Q quarterly report for the period ending on June 30, 2020. "We've got some developments that are going to turn into significant commercial successes," shared Calvert, noting the Company's diversification of its products. "We have a couple of big wins coming to the table, and more after."

Calvert then expanded on the Company's FDA registered personal protection spray Clyraguard. "Clyraguard is a very exciting product. It was developed by our medical subsidiary Clyra Medical," explained Calvert. "It is a [personal protection equipment] (PPE) disinfectant, which is FDA registered, hospital grade, and safe. Literally, you can spray it on your skin and face mask, and it provides an extra layer of protection," said Calvert, adding that the product was proven to inactivate the SARS-CoV-2 (COVID-19) virus in a third party study.

Calvert shared that Clyraguard is in the process of undergoing a multiphase launch. "We have a number of online sellers, and we have some distributors," shared Calvert, adding that a very large distributor is currently preparing to come onboard. "The product is a four ounce bottle. That little bottle lasts about two months," he added, noting that Clyraguard will retail for around $25 per bottle. "There's no odor, stickiness, or residue, and it provides this incredibly effective product."

The conversation then turned to the Company's solution for the current per and polyfluoroalkyl substance (PFAS) water contamination crisis. "The experts say that PFAS touches 98% of the world; it's in your food, it's in your water, it's in products, and it's in coatings," explained Calvert. "Nature won't break them down, and a little bit over a long period of time creates a problem," he added. "Our engineering group came out with a solution, got a grant, proved out the first phase, and we've been advancing that design to be ready for commercialization," said Calvert, before elaborating on the importance and cost of this crisis. "We'll be in commercial trials soon, and it's a significant opportunity."

Calvert then commented on the Company's AOS water treatment technology. "This was another innovative development that provides extremely efficient destruction of micropollutants and efficient disinfection," explained Calvert. "It's a remarkable scientific achievement," said Calvert. He then shared that the Company received a significant funding commitment from a new client, as well as from grant authorities. "The total revenue for the company for that project is going to be about half a million dollars."

To close the interview, Calvert expressed his confidence in the Company's resiliency, as well as the potential of their diversifying portfolio. "We think the future is extraordinarily bright for this company."

To hear Dennis Calvert's entire interview, follow the link to the podcast here: https://audioboom.com/posts/7661365-biolargo-covers-its-diverse-portfolio-with-the-stock-day-podcast.

Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at https://investorshangout.com/.

About BioLargo, Inc.

BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to "make life better". We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, ONM Environmental, Inc. (www.onmenvironmental.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and technology licensor to our subsidiary Clyra Medical which features its breakthrough product Clyraguard (www.clyramedical.com/clyraguard), an FDA Registered, hospital grade disinfectant for personal protective equipment including facemasks, proven 99.999% effective against viruses and bacteria, and safe for skin, as well as its other products offering gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

Contact Information

Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863

Safe Harbor Act

During the course of the stockholder presentation, BioLargo may make "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995, regarding future events or the future financial performance of the company that are subject to change. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

About The "Stock Day" Podcast

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America. Stock Day recently launched its Video Interview Studio located in Phoenix, Arizona.

SOURCE:
Stock Day Media
(602) 821-1102

Monday 17 August 2020

BioLargo Resilient Through COVID-19 Pandemic, Clyraguard Sales Ramping Up

Including Highlights from BioLargo’s Second Quarterly Report of 2020

Westminster, CA – August 17, 2020 – BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies and a full-service environmental engineering company, provided an overview today on recent highlights for its business units. This overview coincides with the filing of BioLargo’s 10-Q Quarterly Report with the SEC for the period ended June 30, 2020 (www.biolargo.com/sec-filings).

Highlights include:

  • Clyra Medical Technologies launched Clyraguard Personal Protection Spray, a safe, effective, FDA-registered disinfectant designed to decontaminate medical devices such as face masks and other personal protection equipment (PPE). The product has been met with great enthusiasm, and sales are ramping up.
  • As part of a multi-phase product roll-out plan, Clyra secured a $1 million inventory line of credit and formed relationships with three contract-manufacturers that are actively producing Clyraguard. Distribution partners for Clyraguard are just beginning sales activities, having recently received their initial inventory.  Given the sales achieved in recent weeks and volume of orders in process, the company expects to report substantial revenue increases from product sales in the third quarter of 2020. Company management reports that its current manufacturing resources are capable of producing up to one million Clyraguard units per month before it would need to expand with additional contract manufacturers.  
  • BioLargo Water will soon start the first commercial project for its AOS water treatment system, which will be funded by government grants and its client and is expected to generate more than $500,000 USD in revenue over the life of the project.
  • BioLargo Engineering manufactured a medium-scale demonstration pilot prototype of the BioLargo AEC, the company’s per- and polyfluoroalkyl substance (PFAS) water treatment technology. The company will start two field demonstration pilots of the AEC in the coming months.
  • ONM Environmental (formerly Odor-No-More, Inc.) is restarting multiple capital projects that were on hold due to the COVID-19 pandemic, and was recently notified of an award for a project valued at approximately $130,000.
  • BioLargo’s company-wide revenue for the three and six months ended June 30, 2020 was $418,000 and $856,000, which is a 2% decrease and 8% increase over the same periods in 2019. Sales at the company’s operating divisions decreased at the start of the pandemic, but are now rebounding.
  • BioLargo continues to strengthen its balance sheet as it converts approximately $3,500,000 of debt to equity since December 31, 2019 through August 2020.

BioLargo President & CEO Dennis P. Calvert commented, “In the COVID-19 pandemic, we demonstrated our resiliency as we managed to maintain stable operations, cleaned up our balance sheet, developed and launched a brand new product (Clyraguard) to help frontline workers battling the pandemic, and made multiple adaptations to be a strong solutions provider in a global pandemic. We’re now seeing our hard work translate to increasing sales. We have a number of new relationships with distribution partners that we plan to share more information about as they begin selling Clyraguard. While the commercial opportunity for Clyraguard is immediate and has the potential for significant commercial success, the rest of our technology portfolio continues to advance, and we remain confident about their future.”



About BioLargo, Inc.

BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to “make life better”.  We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, ONM Environmental, Inc. (www.onmenvironmental.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and technology licensor to our subsidiary Clyra Medical which features its breakthrough product Clyraguard ( www.clyramedical.com/clyraguard), an FDA Registered, hospital grade disinfectant for personal protective equipment including facemasks, proven 99.999% effective against viruses and bacteria, and safe for skin, as well as its other products offering gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

During the course of the stockholder presentation, BioLargo may make “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995, regarding future events or the future financial performance of the company that are subject to change. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

 

Tuesday 4 August 2020

BioLargo sales climb as balance sheet improves

Westminster, CA – August 4, 2020 – BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies and a full-service environmental engineering company, announced today that company-wide sales in July had more than doubled its historical monthly average. Led by subsidiary Clyra Medical’s introduction of Clyraguard Personal Protection Spray, an FDA registered disinfectant for PPE such as facemasks. With first product deliveries to customers in late July, 2020, production ramping up, and distribution channels forming, management is excited about the product’s future prospects. 

Additionally, BioLargo announced that since December 31, 2019, it had converted more than $3,100,000 principal amount of debt to equity, and that an additional $414,000 would convert to equity over the next 45 days, bringing the total to approximately $3,550,000 in debt conversion to equity.  The Company has also reached agreement with holders of approximately $550,000 of debt due in August, 2020, to extend by one-year the maturity dates, and convert a portion of principal into equity. (See Form 8-K filed August 4, 2020.)

The remaining note obligations of BioLargo after these conversions will be approximately $2,213,000: (i) $1,007,000 owed by Clyra Medical to Scion Solutions, which is paid out of stock sales and revenues; (ii) $600,000 due August 9, 2021, which may be converted at the holder’s option; (iii) $406,000 due August 12, 2021, which may be converted at the holders’ option; (iv) $100,000 due April 20, 2021, which BioLargo intends to convert to equity at maturity; and (v) $100,000 due on investor demand.  

Dennis P. Calvert, BioLargo’s President & CEO commented, “Our team at Clyra Medical developed Clyraguard in response to the COVID-19 pandemic, and we are proud that they could develop the product, secure FDA registration, secure raw materials, source FDA compliant manufacturing, and deliver product to customers in only a matter of months. We are proud of our team and this product that we believe is vital to help front line workers, and all of us, during these turbulent times. I am personally excited about the prospects of this product, and look forward to reporting more information in our SEC filings.”

Calvert added, “The continued balance sheet improvements are dramatic.  We have been diligent to move away from convertible debt instruments in favor of equity-based transactions for new capital, and have not taken in any new convertible debt since September of 2019, so as to eliminate the extremely expensive non-cash interest expense. We plan to continue to this focus into the future. As we are emerging from the height of the COVID-19 crisis, we are glad to see capital projects being restarted which bodes well for ONM Environmental, BioLargo Engineering and BioLargo Water. We were recently notified of an award of public funding to support our first commercial installation of our AOS system and BioLargo Engineering is preparing for commercial trials for our PFAS solution (the BioLargo AEC) in the coming months.

We will continue to update the information available as more business develops and sales continue to rise.”














About BioLargo, Inc.

BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to “make life better”.  We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, ONM Environmental, Inc. (www.onmenvironmental.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and technology licensor to our subsidiary Clyra Medical which features its breakthrough product Clyraguard ( www.clyramedical.com/clyraguard), an FDA Registered, hospital grade disinfectant for personal protective equipment including facemasks, proven 99.999% effective and safe for skin, as well as its other products offering gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

During the course of the stockholder presentation, BioLargo may make “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995, regarding future events or the future financial performance of the company that are subject to change. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.